Health Care • Biotechnology: Pharmaceutical Preparations
$3.58 ▼ -0.23
(-6.04%)
MKT CAP: $33.5M • VOL: 176.2K
52W L $3 52W H $12
ROARABLE / RQD
D- • 36/100
PIOTROSKI
3 / 9
ACET // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$122.1M | -$127.6M | -$152.0M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$116.8M | -$117.1M | -$142.7M |
| EBITDA (Normalized) | -$120.7M | -$126.7M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$95.2M | -$92.4M | -$93.7M |
| Capital Expenditures (CapEx) | $1.7M | $1.1M | — |
| Free Cash Flow (FCF) | -$97.0M | -$93.5M | -$93.7M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $38.9M | $56.5M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $159.2M | $186.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ACET.